Drug intelligence / Profile preview

CILO-202

Development stage: Preclinical
Lead developer: Ciloa
Modality: Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems

Overview

CILO-202 is a preclinical-stage therapeutic candidate developed by Ciloa for the treatment of various cancers. It is based on Ciloa's proprietary platform for bioengineering small extracellular vesicles (sEVs), also known as exosomes. This technology allows for the production of customized exosomes that express specific proteins in their native conformation on the vesicle surface or carry therapeutic payloads. By utilizing these naturally occurring delivery vehicles, CILO-202 aims to provide a targeted approach to oncology treatment with potentially improved stability and reduced immunogenicity compared to synthetic delivery systems.

Beyond the preview

Go deeper on CILO-202.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CILO-202.

Explore the full profile